Deleterious de novo SHANK2 mutations have always been identified in a heterozygous state in patients with ASD, intellectual disability, attention deficit and hyperactivity disorder as well as language impairment, with one allele unaffected2–5. This evidence concerns the gene SHANK2 and attention deficit-hyperactivity disorder.